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Genome rearrangementsrmination factor, speciﬁcally present at sites of myogenesis. Surprisingly, during
mouse development, this gene is also transcribed in restricted areas of the central nervous system, although
the Myf5 protein is not detectable. We have investigated the regulation of Myf5 expression in the central
nervous system. Using both in ovo electroporation in the chick embryo and transgenesis in the mouse, we
show that regulatory sequences that direct neuronal Myf5 transcription are present in a distal element
located between −55 and −54.3 Kb from the Myf5 gene. An Oct6/Tst1 binding site is required for embryonic
brain expression, and in the Oct6 mutant mouse embryo, Myf5 transcripts are no longer detectable in the
brain. The Wnt-β catenin signalling pathway is also implicated. Finally we show that post-transcriptional
regulation of Myf5 gene expression involves miRNA repression acting through the Myf5-3′UTR.
© 2008 Elsevier Inc. All rights reserved.Introduction
Myf5 is a key myogenic determination factor, essential, with Mrf4
and MyoD, for initiating skeletal muscle formation in the mouse
embryo (Kassar-Duchossoy et al., 2005; Tajbakhsh and Buckingham,
2000). This family of bHLH transcription factors, when overexpressed
in non-muscle cells, can convert them to the myogenic programme
(Weintraub et al., 1991), a remarkable property which reﬂects their
capacity to remodel chromatin (Gerber et al., 1997). As would be
expected, these myogenic regulatory factors are skeletal muscle
speciﬁc and their genes are transcribed at sites of myogenesis. This
is the case forMyf5which is transcribed at a high level at the onset of
myogenesis in the somite and limb bud. However, unexpectedly, some
neuronal cells located in restricted domains of the mouse central
nervous system (CNS) were also found to transcribe the Myf5 gene
during embryonic development and in the adult (Tajbakhsh and
Buckingham, 1995). In the brain, these domains are located in the
ventral mesencephalon (ventral prosomere p1) from embryonic day).
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l rights reserved.8.5 (E8.5), as well as in the ventral prosencephalon (ventral prosomere
p4) from E10, and in the ventral neural tube. The Myf5 transcribing
cells were further characterized at the molecular and cellular level to
explore the neuronal expression of Myf5 and its possible function in
the CNS (Daubas et al., 2000). Myf5 transcripts are present and
correctly spliced in the brain but, using speciﬁc antibodies, Myf5
protein cannot be detected in these neurons in vivo (Daubas et al.,
2000). Furthermore in the Myf5nLacZ/nLacZ mutant, there is no
detectable disorganisation of β-galactosidase positive cells generated
from the Myf5nLacZ allele, nor is there a detectable neuronal
phenotype. This suggests that post-transcriptional mechanisms
prevent accumulation of the protein in vivo. Interestingly, when the
neural tube is dissociated in culture, such mechanisms no longer
function, and Myf5 protein accumulates, leading to myogenic
conversion of some neurons (Tajbakhsh et al., 1994). In the embryonic
brain, Myf5 transcription occurs in neuronal cells in the vicinity of
other cells expressing Wnt1 or Shh and experiments with brain
explants co-cultured with Wnt1 expressing cells showed an enhance-
ment of Myf5 transcription (Daubas et al., 2000). Both Shh and Wnt
signalling pathways are implicated directly in the activation ofMyf5 in
myogenic cells of the somites (Tajbakhsh et al., 1998; Borycki et al.,
1999), where an enhancer element that directsMyf5 expression to the
epaxial somite is a direct target of Shh (Gustafsson et al., 2002; Teboul
et al., 2003) and canonical Wnt (Borello et al., 2006) signalling. It was
proposed that the deployment of the same signalling molecules at
different sites in the embryo may therefore result in the fortuitous
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in its complex developmental regulation, have now been character-
ized (Buchberger et al., 2003; Carvajal et al., 2001; Hadchouel et al.,
2000, 2003; Summerbell et al., 2002; Zweigerdt et al., 1997). The
spatio-temporal expression of Myf5 at sites of myogenesis in the
embryo and in the adult is controlled by distinct sequences and,
furthermore, within a single site in the embryo, different regulatory
subdomains have been identiﬁed. Contrary to expectation, a 2.9 Kb
sequence, located between −56.6 and −53.7 Kb upstream of Myf5,
speciﬁcally targets the expression of a transgene to the sites of the
endogenous gene expression in the CNS. Moreover, transgenic
analysis with a BAC clone carrying the whole Mrf4–Myf5 locus, with
this domain deleted, shows that brain expression is no longer
observed (Hadchouel et al., 2003). These results indicated that speciﬁc
DNA sequences are involved in Myf5 neuronal expression rather than
its fortuitous activation in CNS structures due to mis-ﬁring of
myogenic regulatory elements.
We have now analyzed the 2.9 Kb fragment in more detail in order
to better understand the molecular mechanisms involved in this
unexpected activation of Myf5. In ovo electroporation in the neural
tube of the chick embryo with DNA subfragments from the murine
−56.6/−53.7 Kb region followed by transgenesis in the mouse embryo,
led to the deﬁnition of a shorter 737 bp CNS regulatory fragment that
directs Myf5 expression in speciﬁc sites in the brain where the
endogenous gene is expressed. Together with a more proximal region
(Summerbell et al., 2000), it is also responsible for transcription in the
neural tube. This −55/−54.3 Kb sequence responds to the Wnt-β
catenin dependent signalling pathway. We also show that the the POU
transcription factor Oct6/Tst1, expressed in p1/p4 in the brain, targets
this sequence and indeed in the Oct6mutant mouse,Myf5 transcripts
are not detectable in the brain. The presence of this CNS regulatory
sequence appears to be unique to the mouse Mrf4–Myf5 locus, since
we did not ﬁnd a homologous region in the vicinity of the locus in the
genomes of other vertebrates. We therefore conclude that it is the
result of a recent rearrangement in the mouse genome. Post-
transcriptionnal regulation is required to safeguard the organism
from inappropriate accumulation of Myf5 protein and myogenic
conversion in the central nervous system. Through the expression of a
reporter gene, we show that miRNAs acting on the Myf5-3′
untranslated region (UTR) repress protein expression both in vitro
and in vivo, thus providing a protective mechanism.
Materials and methods
In ovo electroporation, detection of GFP and LacZ activities
Fertilized chicken eggs (SFPA, Nantes, France) were incubated at
38 °C until embryos reached the Hamburger-Hamilton (HH) stages 11–
13 (Hamburger and Hamilton, 1992), and the embryos were visualised
as previously described (Scaal et al., 2004). DNA solutions for injection
were preparedwith 0.2% Fast Green dye (Sigma), to allow visualisation
of the solution during injection. A reporter plasmid, pCIG (Megason
and McMahon, 2002), was included in the solution at 0.5–1 μg/μl to
monitor the efﬁciency of DNA incorporation into the neural tube. The
DNA solution was injected by mouth with a drawn-out glass capillary
(GC100-T, Harvard Apparatus) into the neural tube at the caudome-
dullary junction and electroporated into half of the neural tube with a
BTX Electro Square Porator ECM 830 (Genetronics) conﬁgured to
deliver 5×50 ms pulses of 25 V across the embryo through a pair of
gold-plated electrodes 5 mm in length, 0.5 mm in diameter
(Genetrods Model 512, Genetronics, Inc.). Two ml of Hanks balanced
salt solution (Sigma) containing penicillin and streptomycin were
placed on the embryo just before electroporation. The region where
the shell had been cut was coveredwith adhesive and the egg replaced
in the incubator for 1 day until analysis. GFP activity was visualized
using a Zeiss Stemi SV11 UV binocular microscope (using a Nikon ACT-1 image capture software). Only living embryos showing a GFP-
positive neural tubewere harvested, dissected, rinsed in PBS and ﬁxed
in 4% paraformaldehyde for 15min. Embryoswere individually stained
overnight at 37 °C in an X-Gal solution as previously described
(Tajbakhsh et al., 1994).
Plasmid transgene constructions and generation of mutations
A 2.9 Kb AvaI-AccI fragment was subcloned into pbaMyf5nLacZ as
described in (Hadchouel et al., 2003), to create the −56.6/−53.7 ba-
Myf5nLacZ construct. The fragments −56.6/−55, −55/−53.7, −55/−54.3,
−55/−54.5, −54.8/−54.3 and −54.8/−54.5 Kb were synthesized by PCR
using the Advantage 2 Taq polymerase (Clontech) with XhoI and
HindIII sites added to 5′ and 3′ primers, respectively. The forward and
reverse primers (Eurogentec) used to generate the −56.6/−55, −55/
−53.7, −55/−54.3, −55/−54.5, −54.8/−54.3 and −54.8/−54.5 Kb frag-
ments were, respectively, For (5′ AAA CTC GAG GAG TGA TGG GTT CAT
TAG TGT GC 3′) Rev (5′ AAA AAG CTT GGC TCA GGC TGC TGT TCA TCT
TAG 3′); For (5′ AAA CTC GAG CTA AGA TGA ACA GCA GCC TGA GCC 3′)
Rev (5′ AAA AAG CTT GTC TAC TGA TCC ATC ATT TCA GCC 3′); For (5′
AAACTCGAGCTAAGATGAACAGCAGCC TGAGCC3′) Rev (5′AAAAAG
CTT GGC TAC TCA TGA GAC TAT TTC AGG 3′); For (5′ AAA CTC GAG CTA
AGATGA ACAGCAGCC TGAGCC 3′) Rev (5′AAAAAG CTTACATGCGTA
AATATC ATG GG 3′); For (5′ AAACTC GAGAGGGGA ACT CAC CAAGGC
TCT 3′) Rev (5′ AAA AAG CTT GGC TAC TCA TGA GAC TAT TTC AGG 3′);
For (5′ AAA CTC GAG AGG GGA ACT CAC CAA GGC TCT 3′) Rev (5′ AAA
AAGCTTACATGCGTAAATATCATGGG3′). The PCRproductswereﬁrst
cloned into a pGEM-T Easy vector (Promega) before being re cloned
into either baMyf5nLacZwhich has an SV40 polyadenylation sequence
or upstream of a human β-globin minimal promoter driving a
cytoplasmic LacZ reporter with an SV40 polyadenylation sequence, in
plasmid PGZA, a pBluescript KS (+) based derivative of BGZ40 (Yee and
Rigby, 1993).
Mutations of putative binding sites, T1, T2, T3, T4, G L and O, were
performed using the subclone −55/−53.7 Kb in a pGEM-T Easy vector
(Promega). The plasmid was ampliﬁed by PCR, using Expand High
Fidelity PCR system (Roche) and 2 primers, Reverse and Forward,
complementary in their 5′ extremities were used to generate a new
restriction site, absent in the original plasmid. For putative binding
sites T1, T2, T3, T4, G, L and O (see Fig. 2) these primers (Eurogentec)
were respectively, ForMutT1 (5′ CTG GAT CCG TCA GAG TCA AAC TAT
AAA TAG 3′), RevMutT1 (5′ ACG GAT CCA GCC AAC AGC CAG TTA CCA
GGC 3′); ForMutT2 (5′GCGATATCAAGAGCATTGTTGCTTATATCC 3′),
RevMutT2 (5′ TTG ATA TCG CAA CAG GAG GCC CCA AGT ATC 3′);
ForMutT3 (5′ TTT CTA GAA GC G CCT GGT AAC TGG CTG TTG GCT GG
3′); RevMutT3 (5′ CTT CTA GAA ACA GCA TTC TAA GAC TAG AGA TCT
TTG 3′); ForMutT4 (5′ATC CCGGGC ACGGTC TTT CTC TGC CTT TCC TCT
TTC 3′); RevMutT4 (5′ TGC CCG GGA TTG ACT TGA AAA TGA TAC AGC
TTG G 3′); ForMutG (5′ CAA AGA TCT CTA GTC TTA GAA TGC TGT TCA
AAC TAG C 3′), RevMutG (5′ TAG AGA TCT TTG TTC TGA TTA GGA CAT
AGA GCC TTG G 3′); ForMutL (5′ CTC CCG GGT CTT TAC ATC ACC TGA
AAT AGT C 3′), RevMutL (5′ GAC CCG GGA GTA GGT TTT TCC ATT TGA
ATG 3′); ForMutO (5′ AGC CCG GGG CTC AGG CTG CTG TTC ATC TTA G
3′), RevMutO (5′ GCC CCG GGC TAA TGA GAA GAT AAA GGG GAA GGA
TTC 3′). New BamHI, XbaI, SmaI,EcoRV, BglII and SmaI sites were
respectively introduced to create Mutations T1, T2, T3, T4, G, L and O
(indicated as bold letters in the primer sequences). After ampliﬁcation,
the original DNA matrix was eliminated after digestion by DpnI
enzyme at 37 °C for 2 h, itself inactivated at 80 °C for 20 min, The PCR
product was linearized by the enzyme for which a new restriction site
was created, puriﬁed, ligated to itself using a rapid DNA ligation kit
(Roche) and used to transform XL1 Blue bacteria (Stratagene). All the
mutations were veriﬁed by nucleotide sequencing (GenomeExpress,
France). The complete full length sequence of the mouse Myf5 3′UTR,
including its own polyadenylation signal, was synthesized by PCR
using the following oligos: For (5′ AAAGCG GCC GCC TCC TTT AAA TAT
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GTA C 3′), cloned in the pGEM-T Easy vector (Promega) and veriﬁed by
sequencing before generating the −58/−54 and −55/−54.3 baMyf5n-
LacZ-Myf5-3′UTR-polyA constructs.
In order to create the −55/−54.3 baMyf5nLacZ-Myf5-mut3′UTR-
polyA construct, a 1152 bp SacII/NotI fragment containing the Myf5-
mut3′UTR sequencewas cloned to replace a SacII/XbaI fragment into a
pSKnLacZ-Myf5-3′UTR construct. From this plasmid, a SacII/NdeI
fragment was cloned in the SacII-NdeI sites of a −55/−54.3 baMyf5n-
LacZ-Myf5-3′UTR to change the bona ﬁde Myf5-3′UTR by the mutated
one. In order to insert 5 copies of amiR-31 binding site into the SV40 3′
UTR, a 110 bp fragment from the Myf5 3′-UTR, including the putative
miR-31 binding site plus its 5′ and 3′ ﬂanking sequences, was
ampliﬁed by PCR using oligonucleotides with SﬁI sites (in bold): 5′
GGC CCC CCC GGC CTG AAG CTG AAG GAA AGA AAA GC 3′ (For-SﬁI)
and 5′ GGC CGG GGG GGC CTG ACT TTC AGT TAA ATC TAT TTT C 3′
(Rev-SﬁI). Under controlled ligation conditions, a 550 bp fragment
corresponding to 5 copies of the miR-31 binding sequence was
obtained, sequenced, blunt ended and cloned into a unique blunt MfeI
site in the SV40-3′UTR, in the pSKnLacZ-polyA vector. After sequencing
to verify the orientation, a 950 bp NotI/NdeI fragment representing
the SV40-3′UTR with the miR31x5 concatemer was introduced into
the −55/−54.3 baMyf5nLacZ-SV40 polyA, in order to exchange the
wild type SV40 sequence by the modiﬁed one.
Plasmids
The β-Catenin dominant negative construct was generated as
follows: A ﬂag-tag and nls were inserted in the polylinker of
pCDNA3.1(+) (Invitrogen, CA) using annealed primers. An EcoRV site
was also added with a T3 promoter sequence in the PmeI site in 3′
of the polylinker. An EcoRI 300 bp fragment of β-Catenin containing
the ATG and encompassing an XhoI and EcoRI sites was ampliﬁed
by PCR, sequenced and cloned into the EcoRI site of pCDNA3.1,
allowing in-frame translation of β-Catenin with the Flag tag and nls
sequence. The remaining 3′ sequence of β-Catenin was obtained
from pCS2-β-Catenin (gift of Pr G. Cossu, Milano, Italy) and a 2.2 kb
XhoI-XhoI fragment was cloned in between the XhoI sites of the
ﬂag-nls-5′β-Catenin and pCDNA3.1. 3′ trunction of β-Catenin was
achieved by EcoRV digest followed by religation on itself, leading to
deletion of the last 75 amino acids of β-Catenin. The Tcf3 dominant
negative construct was generated as follows: pCDNA3.1 (+) mTCF3
was obtained from G. Cossu. An HincII-XbaI fragment which deletes
69 amino acids of mTcf3 was cloned in frame into the NotI-XbaI of
the same pCDNA3.1-ﬂag-nls vector. In-frame cloning was veriﬁed by
sequencing. Primer sequences and other cloning details can be
obtained on request to F.R. Human β-Globin LacZ plasmid (pBGZ40)
was originally described in (Yee and Rigby, 1993).
In situ hybridization on cryostat embryo sections
Oct6−/− mutant embryos, described in (Jaegle et al., 1996), were
kindly provided by P. Topilko and P. Charnay (Ecole Normale
Supérieure, Paris). Genotyping of the embryos was done by PCR
with the following Oct6 speciﬁc oligos: For (5′ AAG AAG CGC ACG TCC
ATC GA 3′) and Rev (5′ CC CAG CTC CCC AGG CGC ATA 3′) for detection
of the wild type allele and NeoFor (5′ CTA TCG CCT TCT TGA CGA GTT
CTT C 3′) and Rev (5′ TTG CAGAAC CAGACACGC AC 3′) for detection of
the recombinant Neo/Oct6 allele. Fixation of the embryos and
preparation of sections of 50 μm of thickness on SuperFrost Plus
slides (Menzel-Glaser) was carried out as described in the in situ
hybridization protocol, used with digoxigenin-11-UTP labeled anti-
sense riboprobes (Henrique et al., 1995), with modiﬁcations (http://
www.hhmi.ucla.edu/derobertis/). The Myf5 and Shh riboprobes were
as previously described (Ott et al., 1991) (Daubas et al., 2000). Three
independent Oct6−/− embryos were tested.Transgenesis
Generation of transgenic embryos and analysis of transgene
expression were carried out as described in (Hadchouel et al., 2003).
Luciferase assay
The Myf5 3′UTR sequence was ampliﬁed by PCR using forward 5′
AAA TCT AGA ACT CTC TCC CGA TGA TCA CTC C 3′ and reverse 5′ CTC
CTT TAA ATA TTT TAT TTG ATA ATA ATA GTA C 3′) primers, cloned into
the pGEM-T Easy vector (Promega) and then into the NotI site
downstream of the hRluc gene in the psiCHECK-2 vector (Promega).
This vector contains an additional ﬁreﬂy luciferase (Fluc) gene as an
internal control. Predicted miRNA target sites were mutated using a
QuickChange Multi Site-Directed Mutagenesis kit (Stratagene) on the
Myf5 3′UTR cloned into a pGEM-T Easy vector, and subsequently
subcloned into psiCHECK-2 after sequence veriﬁcation. Primer
sequences for these mutations are available upon request.
293 cells were grown to 70% conﬂuence in DMEM supplemented
with 10% fetal calf serum in 12-well plates, transfected using
Lipofectamine-2000 (Invitrogen), according to the manufacturer's
instructions, and grown with cell cycle synchronization as previously
described (Vasudevan et al., 2007). Transfections were carried out
with 50 ng psiCHECK-2 construct and 20 nM ﬁnal concentration of
miR-20 and miR-31 double stranded precursor molecules or antag-
omirs (Ambion). For normalization, psiCHECK-2 constructs were
cotransfected with 20 nM miR-431 double stranded precursor
molecules, which are not predicted to target the Myf5 transcript, or
a 20 nM antagomir negative control nucleotide, which does not target
a known microRNA (Ambion). The luciferase assay was performed
with the Dual Luciferase Reporter Assay System (Promega) according
to the manufacturer's instructions.
To conﬁrm the endogenous presence of miR-20 and miR-31 as
targets of antagomirs, total RNA from 293 cells was isolated by Trizol
(Invitrogen) and real-time PCR ampliﬁcation of miRNAs was
performed as previously described (Shi and Chiang, 2005) using the
standard protocol of the ABI Prism 7000HT Sequence Detection
System. Primers speciﬁc to miR-20 and miR-31 were 5′-taaagtgctta-
tagtgcaggtag-3′ and 5′-aggcaagatgctggcatagctg-3′, respectively.
Mutated primers miR-20⁎ and miR-31⁎ were 5′-taaagtCGAtatagtg-
caggtag-3′ and 5′-aggcaaCTAgctggcatagctg-3′, respectively.
MicroRNA in situ hybridization
Whole mount in situ hybridization with locked nucleic acid
probes (Exiqon) was performed essentially as described previously
(Kloosterman et al., 2006) with the exception that 60% formamide
was used in the hybridization mix.
Results
Identiﬁcation of a 737 bp fragment that directs transgene expression to
neuronal sites of Myf5 expression
A genomic sequence comprised between −56.6 and −53.7 Kb
upstream of the Myf5 gene is sufﬁcient to direct the activation of a
baMyf5nLacZ reporter plasmid in the neuronal structures where the
mouse Myf5 gene is transcribed during development (Hadchouel et
al., 2003). In order to better delineate the nucleotide sequences
involved in this unexpected transcriptional activation, we used in ovo
electroporation into the neural tube of the chick embryo as a rapid and
simple test for identifying regulatory sequences. The −56.6/−53.7 Kb
fragment was cut into subfragments which were cloned upstream of
different promoters and a reporter LacZ gene (see Table 1). The
reporter construct to be tested was electroporated into neural tubes of
chick embryos at 2 days of development (stages HH11–13), together
Table 1
LacZ expression levels obtained with different subfragments of the −56.6/−53.7 DNA region, electroporated into the chick neural tube
The left part of the table schematically represents the structure of the different minimal promoter/LacZ constructs (baMyf5nLacZ or human-β GlobinLacZ) and the fragments
cloned upstream of them. The upper left part represents the structure of the promoter/reporter constructs used. Lengths are indicated either in kilobase pairs (Kb) or base pairs (bp)
at the left of each fragment. Numbering is relative to the Myf5 ATG start codon (+1). ba, branchial arch element; Cap, Myf5 start of transcription; n, nuclear localisation sequence;
h, human. The right part of the table indicates, for each electroporated construct, the number of Xgal-positive neural tubes in the total number that were GFP-positive and the
intensity of the Xgal staining, estimated by eye (+, ++ and +++ respectively corresponds to a faint, medium or high signal).
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Fluorescent Protein (GFP), to visualize the electroporated cells. To
determine the global activity of the test construct, the intensity of X-
Gal staining was visually estimated the next day; observations were
limited to neural tubes of living embryos in which the GFP signal was
clearly positive, reﬂecting efﬁcient electroporation.
Subfragments of the −56.6/−53.7 Kb region were cloned into the
pSK-baMyf5nLacZ plasmid that had been used in previous transgenic
experiments (Hadchouel et al., 2000, 2003). In this plasmid, a 2785 bp
sequence (baMyf5) lying 5′ to theMyf5 ATG codon within the locus, is
inserted upstream of the nLacZ reporter (see Table 1). This region
includes a 1109 bp branchial arch element (ba), characterized by
Summerbell et al., 2000 and used here as a positive control in mouse
transgenic experiments (see Hadchouel et al., 2000), a putative 422 bp
proximal neural tube element (Summerbell et al., 2000), and the
minimal Myf5 promoter with the 5′ UTR region of the Myf5 gene
(136 bp). Upon electroporation, one fragment (−55/−54.3) gave
reproducible strong β-galactosidase activity, compared to the faint
activity obtained with the −56.6/−55 fragment, or with a 290 bpMyf5
minimal promoter alone or with baMyf5nLacZ (see Table 1 and Figs.
1A–D). This last ﬁnding indicates that the proximal neural tube
element is relatively inactive in this system. In order to control
possible effects of these proximal Myf5 sequences on the upstream
fragment, we used another reporter construct that contains the
minimal promoter of the human β-Globin gene regulating LacZ,
previously used for testing enhancer activities (Summerbell et al.,
2000). Although not as strong as the nuclear β-galactosidase signal
obtained with the baMyf5nLacZ reporter, the resulting cytoplasmic
LacZ activity was reproducibly higher with the −55/−54.3 Kb genomic
fragment than with other fragments (see Table 1). These results show
that this 737 bp sequence enhances the transcriptional activity of a
LacZ reporter gene, using two different promoters, in the context of
the chick neural tube.
Using transient transgenesis, we then analyzed the activity of the
−55/−54.3 Kb fragment in vivo, in the mouse embryo at embryonicday E11.5, a time of development whenMyf5 expression in the CNS is
obvious (Daubas et al., 2000). β-galactosidase activity was detected in
the ventral neuroepithelium, at the levels of prosomeres p1 and p4,
and in the ventral neural tube, shown inwhole mount (Figs. 1E and F).
These are the sites where the Myf5 gene is normally transcribed.
Identical transgenic embryos were obtained with the −55/−54.3 Kb
fragment (see Table 3), and the nLacZ expression proﬁle shown in Fig.
1 was conﬁrmed with subfragments of it (see following section). Sites
ofMyf5nLacZ expression in the ventral neural tube (Fig. 1G) and in the
neuroepithelium at the levels of prosomeres p1 and p4 were
conﬁrmed on sections (Figs. 1H and I). Thus, the complete neuronal
proﬁle of Myf5 transcription, previously obtained with a 2900 bp
fragment (−56.6/−53.7), is reproduced by this much shorter 737 bp
fragment.
We examined whether sequences within the mouse −55/−54.3 Kb
region show signiﬁcant homologies with equivalent sequences in the
Mrf4–Myf5 loci of other vertebrate species. Using Ensembl Multi Blast
view (Project Ensembl http://www.ensembl.org/), we blasted the
mouse −55/−54.3 Kb region against whole human, rat, chicken or dog
genomes. No signiﬁcant homologies were found in corresponding
Mrf4–Myf5 loci, except a short 100 bp region in the ratMyf5 locus that
is homologous with the most 3′ extremity of the −55/−54.3 Kb
fragment (see Fig. 2A). The mouse sequence is preceded by an
extensive series of 70 polypyrimidine CT repeats which may be
implicated in DNA rearrangement. This region, with potential
regulatory sites, is presented schematically in Fig. 2B.
The Wnt-β catenin-dependent signalling pathway directly affects
the transcription of Myf5 in the CNS
Shh and/or canonical Wnt β-catenin-dependent signalling path-
ways have been proposed to be, directly or indirectly, involved in the
regulation of Myf5 gene transcription in the embryonic mouse CNS
(Daubas et al., 2000). There are four putative Tcf/Lef (Fig. 2A, sites T1 to
T4, sites T3 and T4 each have a mismatch, consensus 5′ A/T A/T CAAAG
Fig. 1. Visualization of the activity of a −55/−54.3 baMyf5nLacZ construct in the chick neural tube and in neuronal structures in the mouse embryo. (A–D) images from representative
chicken embryos, co-electroporated with pCIG (GFP-plasmid) and either baMyf5nLacZ (A, B) or −55/−54.3 baMyf5nLacZ (C, D). All plasmids were electroporated at 1 μg/μl. (A) and (C)
show visualisation of the GFP expression. (B) and (D) show the β-galactosidase activity after X-Gal staining of embryos shown, respectively, in (A) and (C). In the experiments
presented here, either left (A, B) or right (C, D) sides of neural tubes were electroporated. (E) and (F) are images of a representative −55/−54.3 baMyf5nLacZ transgenic mouse embryo
at E11.5 after X-Gal staining. Extraocular nLacZ expression is ectopic. Expression in the branchial arch is due to the ba sequence present in the plasmid. Expression in the neural tube is
indicated by a white arrow (E), shown in a transverse cryostat section at the interlimb level (dotted line) (G). A close up image of the head is shown in (F). Black arrows indicate the
nLacZ expression in the p1 and p4 regions in the embryonic brain. (H) and (I) are horizontal cryostat sections of the head of the embryo shown in (F), at the level of prosomeres p1 and
p4, respectively. Rostral is up and caudal is down in pictures (H) and (I).
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5′ GACCACCCA 3′) binding sites in the −55/−54.3 Kb sequence. Sites G
and T1,T2 are located in a 310 bp fragment (−54.8/−54.5). β-
galactosidase activity is increased when this short fragment is linked
to a baMyf5nLacZ transgene and electroporated into the chick neural
tube (see Table 1), signifying that the 310 bp fragment enhances
transcription in this context. To test the possibility that Shh or Wnt β-
catenin signalling pathways may regulate this aspect of neuronalMyf5
gene transcription, we co-electroporated dominant negative mole-
cules, acting either on the Wnt β-catenin-dependent or the Shh
pathways, into the chick neural tube together with different baMyf5-
nLacZ plasmid constructs.
We ﬁrst controlled the inhibitory effect of β-catenin and Tcf3
dominant negative molecules by co-electroporating their expression
vectors with a “target” BAT-Gal plasmid in which seven Tcf-bindingsites had been multimerized in front of a LacZ reporter gene (Maretto
et al., 2003). The BAT-Gal vector directed strong β-galactosidase
activity in the chick neural tube. Co-expression of dominant negative
β-catenin or Tcf expressing constructs reduced this activity (results
not shown). When the −55/−54.3 baMyf5nLacZ construct was
introduced into the chick neural tube in the presence of either β-
catenin or Tcf3 dominant negative molecules, β-galactosidase activity
was reduced. This suggests that the transgene is a target of canonical
Wnt signalling (see Table 2).
We also tested the effect of a dominant negative Gli3R construct on
the Myf5 transgene. Gli3R acts as a constitutive repressor of the Shh
response, independent of Shh signalling (Meyer and Roelink, 2003).
Over-expression of Gli3R completely abolished the reporter nLacZ
activation directed by the −55/−54.3 baMyf5nLacZ transgene and also
that of the −55/−54.5 and −54.8/−54.3 baMyf5nLacZ constructs (see
Fig. 2. (A) Nucleotide sequence of the mouse 737 bp CNS speciﬁc element. The coding strand is presented and the potential binding sites for Oct6 (site O), Tcf/Lef (sites T1-4), Gli (site
G) and Lhx3 (site L) are underlined. Grey boxes correspond to nucleotides in agreement with the known consensus. Site T2 is in the reverse orientation. Sites G, T3 and T4 containmis-
matches in the 3′-most positions. Distances relative to the Myf5 ATG start codon are indicated in Kb. The region in bold has 98% homology with the rat sequence. (B) Schematic
representation of regulatory sequences involved inMyf5 CNS transcription. Distal and proximal regulatory elements are indicated within theMrf4–Myf5 locus as well as the location
of binding sites for Oct6, Gli, Tcf/Lef and Lhx3 proteins. Gli and Lhx3 sites, which we subsequently show are not essential for activity, are indicated in brackets.
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plasmid, which contains no Gli sites in this proximal regulatory region.
This suggests that loss of expression may be a secondary effect due to
neural tube dorsalization by Gli3R rather than a direct effect and
indeed the Gli site in the 737 bp fragment is not a complete consensus
sequence.
The role of these Tcf and Gli binding sites was then analyzed in the
mouse embryo. The larger −55/−54.3 Kb fragment in which the two
potential Tcf/Lef (T1 and T2) and the Gli binding sites had beenmutated (Mut T1, T2, G) was placed in front of the baMyf5nLacZ
transgene and tested by transient transgenesis in mouse embryos at
E11.5. Of the eight embryos obtained (see Table 3), six had some β-
galactosidase positive cells in the neuroepithelium at the levels of p1
and p4, although at very variable levels (Fig. 3 and Table 3). The level
of nLacZ expression, as revealed by X-gal staining, was always faint in
neuronal cells of the neural tube, compared to that obtainedwith non-
mutated constructs. The two other Tcf binding sites (T3 and T4) were
mutated in the context of the construct (Mut T1, T2, G) to generate a
Table 2
Effects of inhibiting the Wnt β-catenin dependent or Shh signalling pathways on the
activity of electroporated DNA constructs
Electroporated constructs Xgal+/total GFP+ Xgal staining
−55/−54.3 baMyf5nLacZ 5/5 ++
−55/−54.3 baMyf5nLacZ+βCatenin DNeg 5/5 +/−
−55/−54.3 baMyf5nLacZ+TCF3 DNeg 0/3 −
−55/−54.3 baMyf5nLacZ+Gli3R 0/12 −
−55/−54.5 baMyf5nLacZ+Gli3R 0/3 −
−54.8/−54.3 baMyf5nLacZ+Gli3R 0/2 −
baMyf5nLacZ+Gli3R 0/3 −
−55/−54.3 Mut L baMyf5nLacZ 3/3 +++
For the different plasmids used, the number of XGal positive GFP-positive neural tubes
is indicated. The intensity of the XGal staining was estimated by eye (−, +, ++ and +++
respectively corresponds to a null, faint, medium or high signal). DNeg, dominant
negative.
Fig. 3. Effects of mutating putative Tcf/Lef and Gli binding sites on neuronalMyf5-nLacZ
expression in the mouse embryo. (A, C, E) and (G,I) are, respectively, transgenic −55/
−54.3 MutT1/T2/G baMyf5nLacZ and −55/−54.3 MutT1/T2/T3/T4/G baMyf5nLacZ
embryos at E11.5 after X-Gal staining. (B, D, F, H, J) are, respectively, enlargements of
embryos (A, C, E, G, I). Some embryos show a visible signal in the ventral brain region p1
(B, D), whereas others show virtually none, notably after mutation of all four Tcf/Lef
sites (see H and J). ⁎ indicate nLacZ expression in the branchial arches due to the ba
element as a control (A, C, E, G, I).
77P. Daubas et al. / Developmental Biology 327 (2009) 71–82−55/−54.3 Kb fragment in which four putative Tcf binding sites and
the putative Gli site were now mutated. All these transgenic embryos
had very low to null levels of nLacZ expression in brain neuroepithe-
lium with more variable residual activity in the neural tube. This
indicates that Tcf sites are involved in the activation ofMyf5 in the CNS
of the mouse embryo.
Different parts of the 737 bp element are responsible for Myf5 neuronal
transcription at different locations — the essential role of Oct6
Two overlapping fragments, encompassing the −55/−54.3 Kb
sequence were tested, namely −55/−54.5 Kb and −54.8/−54.3 Kb
fragments which share a common region but differ in their 5′ or 3′
extremities. When cloned in front of the baMyf5nLacZ reporter, these
fragments always gave robust β-galactosidase activity when tested by
electroporation in the chick neural tube, suggesting that the common
310 bp sequence may direct this transcriptional activation, and indeed
this sequence also shows robust activity (Table 1).
When tested by transgenesis in E11.5 mouse embryos, expression
of nLacZ in the embryonic brain (p1/p4) is obtained with the −55/
−54.5 Kb, but not with the −54.8/−54.3 Kb, fragment (see Table 3;
Figs. 4A and B, compared to C and D). Robust nLacZ expression is
detected in the ventral part of the neural tube of embryos expressing
transgenes regulated by both −55/−54.5 Kb and −54.8/−54.3 Kb
subregions (not shown). Examination of the DNA sequence for
binding sites for transcription factors shows that the 3′ end of the
−55/−54.3 Kb fragment contains a putative site for the binding of the
homeobox containing factor LIM/Lhx3, involved in specifying the
identity of some ventral motorneurons (also with Lhx4) in mammals.
Lhx3 is expressed in the region of the neural tube where Myf5 isTable 3
Summary of transient transgenic embryos obtained and examined at E11.5 days
baMyf5nLacZ transgenes Transgenic embryos p1/p4 NT
(Total number) (Xgal staining)
−55/−54.3 3 3 3
−55/−54.3 Mut T1,T2,G 8 6 6
−55/−54.3 Mut T1,T2,T3,T4,G 7 2 5
−55/−54.5 2 2 2
−54.8/−54.3 2 0 2
−55/−54.8 3 2 1
−55/−54.3 Mut L 2 2 2
−55/−54.3 Mut O 4 0 4
−55/−54.3 baMyf5nLacZ-Myf5 3′UTR-pA 7 2 7
−55/−54.3 baMyf5nLacZ-Myf5 3′UTR-miRMut-pA 6 5 5
−55/−54.3 baMyf5nLacZ-SV40 3′UTR miR31x5 4 0 4
The total number of transgenic embryos is given, together with those expressing
Myf5nLacZ in prosomeres p1 and p4 and/or in the ventral neural tube (NT).transcribed (Sharma et al., 1998). To test for function, we mutated the
TTTAATT consensus site for Lhx3 binding (Fig. 2, site L) in the −55/
−54.3 Kb fragment. In electroporated chick neural tubes, gross
expression of nLacZ was not affected, with the −55/−54.3 MutL
baMyf5nLacZ construct (see Table 2), nor did mutation of the Lhx3
site abolish brain and neural tube expression in transgenic mouse
embryos (Fig. 5A). Lhx3 putative binding sequences are also present
in the minimal Myf5 promoter region (position −120 bp) and more
upstream at −2 Kb. If functional, these sites may be active in control
plasmids −0.29Myf5nLacZ or baMyf5nLacZ (see Table 1). The 5′
extremity of the −55/−54.3 fragment appears to be important for
embryonic brain expression. In the absence of this 5′ sequence,
nLacZ expression is restricted to the neural tube, stopping abruptly at
the junction of the metencephalon with the mesencephalon (Figs. 4C
and D). nLacZ expression is also obtained in the p1/p4 region of the
brain in transgenic embryos with a −55/−54.8 baMyf5nLacZ construct
which lacks the common region (results not shown, see Table 3). Search
for homologies with known transcription factor binding sites in the
−55/−54.8 sequence revealed the presence of a putative binding site for
the POU domain transcription factor Oct6/Tst1 (Fig. 2A), which may
play a role inMyf5 brain expression since the Oct6 gene is expressed at
this stage of development in a very similar area of the ventral midbrain
Fig. 4. Visualisation of representative transgenic embryos at E11.5 expressing the −55/
−54.5 baMyf5nLacZ (A, B) or the −54.8/−54.3 baMyf5nLacZ (C, D) constructs. (B) and (D)
are close ups of head regions shown in (A) and (C). ⁎ in (A) and (C) indicate nLacZ
branchial arch expression, due to the presence of the control ba element in the Myf5
promoter region used. Black arrow in (D) indicates the Met-Mesencephalic region
where the neural tube X-Gal staining stops.
Fig. 5. Oct6/Tst1 is implicated in regulating Myf5 expression in the CNS. (A) XGal
staining of a transgenic embryo at E11.5 expressing −55/−54.3 MutL baMyf5nlacZ.
Mutation L, within a putative Lhx3 binding site, does not abolish nLacZ expression in the
brain. (B) X-Gal staining of an −55/−54.3 MutO baMyf5nlacZ transgenic embryo at E11.5.
Mutation of the putative Oct6/Tst1 binding site abolishes nLacZ expression in the p1/p4
region of the brain, but not in the neural tube. (C) Close up of the brain region of the
embryo shown in (B) (arrows indicate the p1/p4 region). (D, E) Cryostat sections of an
Oct6+/+ embryo (head and tail section in D) and an Oct6−/− embryo (head sections F, G)
at E11.5 hybridized with a Myf5 riboprobe (D, E, G) or with a Shh riboprobe (F) as a
control of hybridization. The Myf5 in situ signal is visible in the neuroepithelium in the
p1 region of the wild type embryo (arrows in D, enlargement in E), but it is absent in
Oct6−/− neuroepithelium (G). Myf5 transcripts are clearly detected in somites of the
tail of the wild type embryo in the transverse section in (D). The black star in (A) and (B)
indicates nLacZ expression in the branchial arch, due to the ba element in the promoter
region used.
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the context of the −55/−54.3 Kb fragment (Fig. 2A, site O) and activity
examined by transgenesis, X-Gal staining at the levels of prosomeres
p1 and p4 is completely abolished at E11.5, although neural tube
staining is still present (see Table 3 and Figs. 5B and C). These results
demonstrate that this putative Oct6 binding site is essential for Myf5
transcription in this area of the embryonic brain and suggests that
Oct6/Tst1 plays a role, via direct binding to this site. To further show
that Oct6 is required for the activation ofMyf5 transcription in the p1/
p4 region, we performed in situ hybridization on sections of either
wild type or Oct6−/− mutant embryos (Jaegle et al., 1996) at E11.5.
Myf5 transcripts were detected in somites and limb buds in both
cases, but were detected only in the ventral neuroepithelium in the p1
and p4 region of wild type, but not of Oct6−/− mutants embryos (Figs.
5D, E, G and data not shown). In this experiment, hybridization with a
Shh probe indicates that the morphology of this region of the brain is
not perturbed in Oct6 mutants (Fig. 5F) where some of the Shh
positive cells co-express Oct6 (Zwart et al., 1996). This ﬁnding
provides additional evidence that the POU transcription factor Oct6
is directly required for Myf5 transcription in the embryonic neuro-
epithelium of the p1/p4 regions of the brain.
The Myf5 3′UTR sequence regulates post-transcriptional accumulation of
Myf5 in embryonic brain structures
As we have already shown, the Myf5 protein is not detectable in
the regions of the CNS where theMyf5 gene is transcribed (Daubas et
al., 2000). Nevertheless when the nLacZ reporter is introduced into a
Myf5 regulated transgene or, by homologous recombination, into the
endogenous Myf5 gene, β-galactosidase protein is present, as evident
by X-gal staining in these sites in the brain and neural tube. In this
reporter transgene, the nLacZ coding sequence is followed by an SV40
3′UTR sequence (Hadchouel et al., 2000; Tajbakhsh et al., 1996a). In
the last few years, it has become evident that the 3′UTR of mRNAs can
be a target of post-transcriptionnal regulatory mechanisms. Micro-
RNAs (miRNAs), which bind to complementary regions of the 3′UTR of
mRNAs with imperfect base-pairing, coordinate the RISC complex,
which inhibits messenger translation and hence protein expression
(Wienholds and Plasterk, 2005).
To identify putative miRNA target sites on the Myf5 3′UTR
sequence, we used miRanda (Enright et al., 2003) and TargetScan
(Grimson et al., 2007) algorithms, since they allow for target
prediction without using conservation amongst species as a criterion,which is precluded by the restriction ofMyf5 transcription in the brain
to rodents. Of the predicted targets, microRNAs in the polyvalent
microRNA cluster miR-17-20, ie/miR-17-5p, miR-18, miR-19 and miR-
20, as well as miR-31, were chosen for further analysis due to their
high scores and multiple target sites (nucleotides 18–43, 106–131,
752–775, 830–852, 990–1014 for the miR-17–20 cluster; nucleotides
101–123 for miR-31) on the 3′UTR of Myf5. We cloned the 3′UTR of
Myf5 and mutated it to disrupt microRNA binding to the predicted
target sites listed above. These 3′UTRs were subcloned downstream of
the Renilla luciferase reporter gene in the psiCHECK-2 construct.
These plasmids were co-transfected with dsRNA precursor molecules
(Ambion) corresponding to miR-20 and miR-31 into 293 cells. In this
system, Renilla luciferase was down-regulated by 43 and 49% for miR-
20 and miR-31, respectively, when co-transfected with the Myf5-3′
UTR (Fig 6A). This down-regulation was largely eliminated when the
predicted target sites were mutated, indicating that these microRNAs
interact with the wild-type, but not the mutated Myf5-3′UTR. Since
both miR-31 and the miR-17-20 cluster are widely expressed across
multiple tissues (Landgraf, 2007), we also considered that the
endogenous presence of miR-20 and miR-31 could affect the basal
level of Renilla luciferase reporter activity, hence possibly limiting the
observed effect of co-transfected microRNAs. First, we conﬁrmed that
293 cells express miR-20 and miR-31 by RT-PCR (Fig. 6B) as well as
miR-17 and miR-18 (data not shown). Next, we co-transfected our
reporter constructs with miR-20 and miR-31 antagomirs (Ambion),
which base-pair with microRNAs, thereby preventing their targeting
of the 3′UTR. As expected, Renilla luciferase activity was upregulated
by 31 and 7% by the co-transfection of antagomirs against miR-20 and
miR-31, respectively, with the wild-type but not mutatedMyf5-3′UTR.
The differences observed between the two antagomirs may reﬂect the
relative abundance of these microRNAs in 293 cells and indeed miR-
Fig. 6.MicroRNA regulation of theMyf5-3′UTR. (A) miR-20 and miR-31 speciﬁcally inhibit luciferase reporter activity in the presence of theMyf5-3′UTR. 50 ng of reporter constructs
psiCHECK-Myf5-3′UTR (left) or psiCHECK-mutMyf5-3′UTR, with miR-20 and miR-31 sites mutated (right), were co-transfected with a ﬁnal concentration of 20 nM double stranded
RNA precursors (grey) or antagomirs (black) for miR-20 or miR-31. Renilla luciferase activity was normalized to ﬁreﬂy luciferase activity, the means and standard deviations from
three independent transfections are shown. Both miR-20 and miR-31 down-regulate luciferase activity for the wild-type, but not mutated Myf5 3′UTR. Conversely, blocking the
activity of endogenous miR-20 and miR-31 with the corresponding antagomir up-regulated luciferase activity for the wild-type, but not mutatedMyf5 3′UTR. Activities are reported
relative to co-transfections with control, non-targeting oligonucleotides (white). (B) RT-PCR products demonstrating the presence of miR-20 and miR-31 in 293 cells were obtained
using microRNA speciﬁc primers, but not similar primers with 3 mutations (denoted by ⁎). 5.8S RNA speciﬁc primers were used as a control. M denotes a 10 bp ladder. (C) A whole
mount E10.5 mouse embryo after in situ hybridization showsmiR-31 expression in different regions, including prosomeres p1/p4 (black arrow) of the brain and in the extremities of
the somites, notably the hypaxial dermomyotome (black arrowhead) but not in the myotome (white arrowhead). (D) Schematic representation of baMyf5nLacZ transgenes with the
upstream regulatory sequence of −55/−54. 3 Kb and four types of 3′ downstream sequences, SV40 3′UTR,Myf5 3′UTR,Myf5 3′UTR miRMut and SV40 3′UTR miR31x5. Putative miR-
17-20 binding sites are in blue and miR-31 in red. X-Gal staining of transient transgenic embryos at E11. 5 with either −55/−54.3 baMyf5nLacZ-SV40-3′UTR (E, F), −55/−54.3
baMyf5nLacZ-Myf5-3′UTR (G, H), −55/−54.3 baMyf5nLacZ-Myf5-3′UTR miRMut (I, J) and −55/−54.3 baMyf5nLacZ-SV40-3′UTR miR31x5 (K, L) constructs. (F, H, J and L) are
respectively close ups of the brain in the region of prosomeres p1 and p4 (as indicated by arrows in F) of embryos shown in (E), (G), (I) and (K). The branchial arch (ba) element
provides a positive control (⁎).
79P. Daubas et al. / Developmental Biology 327 (2009) 71–8220 is much more abundant in mouse and human tissues (Landgraf,
2007). Together, these results indicate that the predicted microRNAs
interact with the 3′UTR of Myf5, but not when the target sites have
been removed, to down-regulate a luciferase reporter gene in
transfected 293 cells.
MicroRNAs of the miR-17-20 cluster are expressed at a number of
sites in the mouse embryo, including in the CNS (Kloosterman et al.,
2006; Lu et al., 2007). In the zebraﬁsh embryo miR-31 is widely
expressed (Wienholds et al., 2005). We examined the expression ofmiR-31 in the mouse embryo and show that it is present in the p1/p4
region of the brain as well as at other sites, including the extremities of
the somites, but not the myotomes (Fig. 6C).
To test the role of the 3′UTR of Myf5 in vivo, we replaced the SV40
3′UTR sequence by theMyf5-3′UTR sequence (including polyadenyla-
tion signals) in the –55/-54.3 baMyf5nLacZ transgene (Fig. 6D) which
normally directs CNS expression (Table 3). X-Gal staining was no
longer detected in p1/p4 in the brain of most transgenic embryos
(Figs. 6E–H, and Table 3). Branchial arch expression due to the baMyf5
80 P. Daubas et al. / Developmental Biology 327 (2009) 71–82region provides a positive control. Some neural tube staining is still
detectable (Fig. 6G). Residual brain expression in 2/7 transgenic
embryos may be due to higher copy numbers of the transgene,
resulting in more transcripts, as also seen when the Myf5-3′UTR
replaces that of SV40 in the robustly expressed −58/−54 baMyf5nLacZ
transgene (Hadchouel et al., 2003), present in multiple copies (results
not shown).
To examine the role of the miRNA binding sites in the Myf5-3′UTR,
we tested the reporter nLacZ expression in the brain of E11.5 embryos
with the −55/−54.3 baMyf5nLacZ-Myf5-3′UTR-miRMut-polyA trans-
gene, in which the 5 putative miRNA binding sites are modiﬁed by
mutations (Fig. 6D). In 5 cases out of 6 (Table 3), expression of β-
galactosidase was now seen in the p1/p4 regions of the brain (see Figs.
6I and J), in comparison with the extinction of expression when these
binding sites are intact (see Figs. 6G and H). This result demonstrates
the importance of these miRNA binding sites in the bona ﬁde Myf5-3′
UTR for post-transcriptional regulation. In a complementary experi-
ment, we inserted into the native SV40-3′UTR ﬁve tandemly repeated
sequences of 110 bp, representing the well conserved putative miR-31
binding site and its ﬂanking sequences present in the Myf5-3′UTR
(positions 60–160). This SV40modiﬁed sequencewas tested in vivo, in a
−55/−54.3 baMyf5nLacZ-SV4O 3′UTRmiR31x5 transgene. In this case, β-
galactosidase activity is no longer detected in p1/p4 regions at E11.5 (4
cases out of 4 — see Table 3), but is still present in branchial arches
(control) and neural tube also targeted by the control region (Figs. 6K
and L).We conclude that expression ofMyf5 in the latter is repressed by
other post-transcriptional mechanisms. This experiment shows that the
β-galactosidase protein is not accumulated in p1/p4 neurons if the
nLacZmRNA possess either a nativeMyf5-3′UTR or a modiﬁed SV40-3′
UTR with additional miR-31 binding sites. This absence of β-
galactosidase activity is speciﬁc to the p1/p4 region of the embryo in
keeping with the presence of miR-31 molecules in this region of the
neuroepithelium acting on target sites present in the 3′UTR.
Discussion
We have dissected the elements responsible for the unexpected
transcription of Myf5 in prosomeres 1 and 4 of the embryonic mouse
brain and in the ventral neural tube. Electroporation of mouse DNA in
the chick neural tube provided a rapid functional screen both for
active subfragments and potential regulatory molecules. This
approach has also been used, for example, to study Krox20 regulation
(Ghislain et al., 2003). Subsequent transgenic analysis and examina-
tion of mutants in the mouse embryo conﬁrmed the activity of
subfragments and added further insights into brain versus neural tube
transcription. We conclude that Oct6 is essential for activity of the
brain subfragment. Wnt signalling acting through multiple Tcf/Lef
sites is also important for CNS transcription. In addition to examining
the activation of this sequence at speciﬁc sites, we have also addressed
the functionally important question of post-transcriptional repres-
sion, demonstrating that the 3′UTR of Myf5 is implicated in this
phenomenon.
Genome organisation
We now deﬁne the sequence at −55/−54.3 Kb responsible for
neuronal transcription of Myf5 in the mouse and show that it is not
conserved in other vertebrates, with the possible exception of the rat
genome which shares a short homology with the 3′ part of the
fragment. This includes the Lhx3 site but not the Oct6 site required for
brain expression. The 5′ part of the CNS sequence may have been lost
in rat or added in mouse during the divergence of rat/mouse genomes
during the last 14 million years. Given its absence in other species, the
location of the CNS sequence 5′ to the Mrf4-Myf5 locus indicates that
it is the result of a relatively recent genome rearrangement, an
example of many such events within the “dynamic genome” (Eichlerand Sankoff, 2003). In this case regulatory sequences were introduced
which impact the Myf5 gene. However, in the absence of a functional
Myf5 protein in the CNS (Daubas et al., 2000), and hence of selection
acting through the gene product, it is probable that regulatory sites,
such as that for Oct6, will not be conserved, so that CNS transcription
of Myf5 presents a transitory problem in terms of genome evolution.
However it is important to understand the mechanisms that underlie
such a phenomenon and how it is circumvented, as discussed in this
work.
The neural tube
There is no evidence of Myf5 transcription in the CNS of other
vertebrates with the exception of the quail where Qmyf5 transcripts
were detected in themedial cells of the posterior neural tube (Borycki et
al., 1997). The quail genome sequence is not yet available but no
homology to the mouse −55/−54.3 Kb sequence was detected around
the chicken Myf5 gene. However comparison of sequences that direct
neural tube transcription is complicated by the presence of an
additional proximal neural tube element of 422 bp at −0.7 Kb from
Myf5 (Summerbell et al., 2000, 2002).
In most of the constructs that we used this proximal region was
present, providing the branchial arch positive control in transgenic
mouse embryos. However, we had previously shown that a −58/−48
tknLacZ construct where the tk promoter replaces the proximal region
of Myf5 also directs activity to the neural tube and electroporation of
the −55/−54.3 h-β-globinLacZ construct in the chick neural tube
conﬁrmed the activity of the 737 bp fragment. In this assay, residual
activity with the proximalMyf5 region alone (Table 1) is probably due
to the neural tube element at −0.7 Kb. In the mouse embryo, negative
transgenic controls, where no brain activity and only occasional neural
tube activity is observed, are provided byother transgenes that include
the proximal neural tube element, with subfragments from the −58/
−48 Kb region that direct expression at myogenic sites only (Bajard et
al., 2006; Hadchouel et al., 2003). Furthermore, mutation of Tcf sites
within the 737 bp CNS fragment affects neural tube expression in the
presence of the proximal baMyf5 region, providing additional evidence
that this proximal region does not direct robust neural tube
transcription. Although this has not been examined at a cellular
level, the proximal neural tube element appears to target a similar
ventral region of the neural tube to that seenwith the 737 bp fragment.
The electroporation experiments in the chick neural tube indicates
that, within this fragment, a 310 bp sequence at −54.8/−54.5 Kb ismost
active. In the mouse embryo, a 3′ fragment that includes this region
(−54.8/−54.3) directs transcription in the neural tube, but not in the
brain. The 3′ part of the CNS sequence contains a Lhx3 consensus site.
This LIM domain transcription factor is expressed in a similar area of
the ventral neural tube, where together with Lhx4, it is involved in
specifying the identity of a subset of neurons (Sharma et al., 1998),
however the Lhx3 site in theMyf5 sequence is not essential for neural
tube expression. The 310 bp subfragment also contains Tcf/Lef binding
sites, as well as a Gli site. Manipulation of dominant negative
constructs in the chick neural tube, together with mouse transgenic
analysis of constructs with sites mutated, show that canonical Wnt
signalling, acting through the Tcf sites, affects neural tube expression.
The electroporation experiments on the other hand do not indicate a
direct effect of Shh signalling and indeed the Gli site is not a complete
consensus sequence.
Transcription of Myf5 in the brain
Mutations of the Tcf sites in the 737 bp sequence also affected
transgene expression in the brain, reducing it to barely detectable
levels. This is consistent with previous observations on the manipula-
tion ofWnt signalling in brain explants which showed an effect on the
transcription of the endogenous targeted Myf5 gene in Myf5nLacZ/+
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locus contain potential Tcf sites, and notably the early epaxial
enhancer at −5.5 Kb where these sites are functionally important
(Borello et al., 2006), responding to Wnt signalling from the dorsal
neural tube that activates Myf5 in the epaxial somites at the onset of
myogenesis (Tajbakhsh et al., 1998).
The −55/−54.3 fragment directs transgene expression in the
ventral neuroepithelium of the brain, at the levels of prosomeres p1
and p4. This is similar to the sites at which the endogenous Myf5
gene is transcribed, but with additional expression extending into the
ventricular zone in prosomere p1 whereas Myf5 transcripts are
restricted to the mantle layer (Daubas et al., 2000; Tajbakhsh and
Buckingham, 1995). This more extensive expression in the subven-
tricular zone of the neuroepithelium had previously been noticed
with the larger −56.6/−53.7 Kb fragment (Hadchouel et al., 2003),
and probably reﬂects the absence of other DNA sequences that limit
its zone of prosomere expression. Analysis of subfragments of the
737 bp sequence demonstrated that brain activity is restricted to the
5′ −55/−54.8 end and depends upon the Oct6 site present in this
subfragment. The importance of Oct6 for transcription of Myf5 in the
brain was conﬁrmed by its absence in the neuroepithelium of
prosomeres 1 and 4 in mutant embryos. Expression of Oct6 in the
developing mouse brain (Zwart et al., 1996) coincides with sites of
Myf5 transgene expression, especially in the neuroepithelium of the
ventral ﬂoor of the neural tube, at the level of the mesencephalic
ﬂexure (Suzuki et al., 1990). Oct6 is not alone in activating Myf5 in
the brain. As discussed, Wnt signalling is also implicated and the
precise pattern of transcription of the endogenous gene also depends
on other regulatory inﬂuences outside of the sequence analysed.
What appears to be fortuitous transcription of Myf5 in the central
nervous system is therefore not due to the introduction of a single
regulatory site as a result of genome rearrangements, but is
orchestrated by a more complex combination of regulators, which
presumably happened to be in the vicinity of the crucial Oct6 site, in
the case of the brain. Given the probable absence of selective
pressure on such sites, different mouse species, such as Mus spretus
or Mus castaneus may show a different pattern of expression from
Mus musculus, or as in the case of the rat, may show no homology
with the 5′ brain subfragment.
The appearance of an inappropriate regulatory sequence in the
vicinity of a gene as a result of genome rearrangements, has often
played an important role in the evolution of gene function (Eichler and
Sankoff, 2003). However it can also be disastrous as in the case of
expression of a myogenic determination factor in the CNS. In such a
situation, repressive mechanisms are vital. Myf5 transcription in the
CNS provides an example of such post-transcriptional protection. We
show that the 3′UTR of the Myf5 mRNA is implicated, since
accumulation of the β-galactosidase transgene product is repressed
when theMyf5-3′UTR is present instead of the SV40 3′-UTR commonly
used with the nLacZ reporter. We identiﬁed miRNAs 17–20 and 31 as
candidates and show that they target the predicted sites in theMyf5-3′
UTR to down-regulate gene expression in a standard luciferase assay.
MiRNAs 17–20 are widely distributed in mice and zebraﬁsh, including
in the CNS (Kloosterman et al., 2006; Wienholds et al., 2005; Lu et al.,
2007). In the zebraﬁsh embryo, they were also described as outlining
the somites, but not in the central compartment of the myotome,
which corresponds to differentiated skeletal muscle (Wienholds et al.,
2005).We now show thatmiR-31 is also expressed at a number of sites
in the mouse embryo, notably in the p1/p4 region of the brain. It is not
present in the forming skeletal muscle of themyotomewhich requires
Myf5, but is concentrated in the extremities of the dermomyotome
where Myf5 is transcribed, but Myf5 function is not required for
delamination of myogenic cells (Tajbakhsh et al., 1996b). Mutating
these miRNA binding sites in theMyf5-3′UTR allows the synthesis and
accumulation of the reporter β-galactosidase protein in the ventral p1/
p4 region of transgenic embryos, and introducing putative miR-31binding sites in the SV40-3′UTR sequence prevents such an accumula-
tion. This therefore provides strong in vivo evidence for the role of
miRNA in preventing inappropriate protein accumulation as a result of
Myf5 transcription in the brain. In conclusion, the answers that we
present here to questions of why a myogenic determination gene is
transcribed in the central nervous system and how functional
consequences are avoided, give insight into potential problems
resulting from genome rearrangement. The Myf5 CNS paradigm
illustrates the regulatory outcomes that ensue.
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